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ABSTRACT
Purpose: The Hlabisa pregnancy cohort was
established to evaluate the effectiveness of prevention
of mother-to-child transmission (PMTCT) guideline
revisions. The objectives of the Hlabisa pregnancy
cohort are to: (1) provide cohort-level information on
maternal health up to 6 weeks postpartum in a high
HIV prevalence setting; and to (2) evaluate aspects of
PMTCT care that have policy relevance.
Participants: The pregnancy cohort is located in
primary health clinics in the Hlabisa subdistrict of rural
KwaZulu-Natal, South Africa. Baseline data collection
between 2010 and 2014 has been completed with the
enrolment of 25 608 pregnancies; age ranged from
15–49 years. Pregnant women were assessed during
routine antenatal visits: first visit, follow-up 1 week
later, 32 weeks (HIV test), infant delivery and 6 weeks
postpartum. Demographic, pregnancy, clinical,
laboratory and HIV data were collected through
Department of Health interviews, laboratory tests and
routine data linkage. Treatment data for HIV-infected
pregnant women were linked to the Africa Centre
Hlabisa HIV Treatment and Care Programme for
detailed antiretroviral therapy (ART) history and
laboratory tests.
Findings to date: The proportion of women initiated
on ART post-2013 were higher (n=437; 100%) than
pre-2013 (n=768; 84.2%). The proportion of women in
care at 6 weeks (73.8%) was also higher post-2013
relative to earlier years (58.5%). The majority of HIV-
infected pregnant women were either on lifelong ART
or ART prophylaxis; pre-2013, ∼ 9.6% of women were
not on any ART. Pregnancy viral load monitoring was
inadequate.
Future plans: This cohort will be used to: (1)
determine HIV acquisition risk during pregnancy and
postpartum; (2) determine the effect of HIV and ART
on birth outcomes; (3) examine the effect of pregnancy
on virological response to ART; and (4) characterise
the effect of sequential pregnancies on access to
clinical care, response to prolonged ART and birth
outcomes.
INTRODUCTION
Prevention of mother-to-child transmission
(PMTCT) of HIV using antiretroviral drugs
can nearly eliminate vertical HIV transmis-
sion and increase maternal survival.1
However, poor delivery of any of the steps in
PMTCT results in cumulative losses of preg-
nant women, raising infant HIV transmission
risk.2 The PMTCT ‘cascade’ highlights the
optimum PMTCT sequence: HIV counselling
and testing at the ﬁrst antenatal visit; CD4
measurement; antiretroviral therapy (ART)
initiation and adherence; and early infant
HIV testing,2 or after cessation of breast
feeding and infant HIV test at 18 months.3
The Hlabisa HIV Treatment and Care
Programme (HHTCP), described previously,4
was a partnership between the South African
Department of Health (DoH) and the
Wellcome Trust funded Africa Centre for
Population Health (Africa Centre). In
January 2010, the Africa Centre established a
pregnancy cohort aligned with the HHTCP
objectives to monitor PMTCT for feedback
to funders. A further objective is to use this
cohort to determine clinical markers related
to pregnancy in this high HIV prevalence
setting. The pregnancy cohort can be linked
with the Africa Centre Demographic
Information System (ACDIS), which has
demographic and health data through
population-based longitudinal surveillance of
∼90 000 people in 12 000 households,
including accurate longitudinal HIV inci-
dence, HIV prevalence and ART coverage
estimates for this subpopulation since
Strengths and limitations of this study
▪ The key characteristic of the Hlabisa pregnancy
longitudinal cohort is size and ability to model
the impact of the HIV programme on the com-
munity through linkage of Africa Centre’s popula-
tion level data with clinical, pregnancy and HIV
data.
▪ Follow-up of HIV-infected mothers is crucial to
monitor adherence to antiretroviral therapy and
disease progression.
▪ Assessment of long-term maternal outcomes
may be limited by high population mobility and
use of routine health sector data.
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2003.5 6 Hence, demographic and health factors related
to the PMTCT programme success can be monitored.
Cohort description
Setting
The predominantly rural Hlabisa subdistrict of
uMkhanyakude in northern KwaZulu-Natal, South Africa
has a population of ∼228 000.5 There are 17 nurse-led
primary healthcare clinics (PHC) with a primary level
district hospital (Hlabisa Hospital), which handles most
of the deliveries. Six DoH clinics and 40% of patients
are located within ACDIS (ﬁgure 1). Household surveil-
lance began in January 2000. Routine household visits
were conducted biannually, and since 2012 three times a
year, to collect information about births, deaths and
migrations. The number of resident and non-resident
females aged 15–49 years in ACDIS from 2010 through
2014, were respectively: 65 454 (27.3%); 65 352 (27.5%);
65 889 (27.7%); 65 092 (27.8%); and 62 705 (27.9%).
Ethics
Owing to the dynamic movement of patients within
antenatal clinics with varying entry times, including
delivery, reliable written informed consent for pregnancy
data linkage with ACDIS was challenging. Additionally,
ACDIS consent is at household level, with either the
household head providing verbal consent for surveys to
be conducted, or a proxy in the absence of the house-
hold head. We therefore requested a waiver of written
informed consent for pregnancy and ACDIS data linkage
from the University of KwaZulu-Natal Biomedical
Research Ethics Committee (E134/06). Instead, women
attending antenatal clinics gave verbal consent to link
their details with ACDIS data.
Who is in the cohort?
From 1 January 2010 to December 2014, all pregnant
women attending antenatal care (ANC) for the ﬁrst time
at PHC clinics in the subdistrict entered the cohort auto-
matically. Data were initially collected from all 17 PHC
clinics in Hlabisa up to 2012; thereafter, since funding was
restricted, the data collection focal point became six PHC
clinics within ACDIS and one clinic located just outside
the surveillance due to the proximity to the national road.
The cohort has completed enrolment for 25 608 preg-
nancies recorded from 1 January 2010 until 31 December
Figure 1 Africa Centre surveillance area showing the position of Hlabisa Hospital with an on-site clinic and 16 peripheral clinics
in the Hlabisa subdistrict, KwaZulu-Natal, South Africa. The Hlabisa subdistrict encompasses the area to the bottom-right of the
map which includes Mtubatuba and Zwenelisha clinics.
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2014 (ﬁgure 2). A secure database system was developed
to capture data on women from the ﬁrst antenatal visit
through delivery up to 18-month infant follow-up.
Data from 7634 HIV-infected pregnant women have
been linked with the Africa Centre HHTCP database to
provide details on HIV treatment and monitoring, includ-
ing postpartum follow-up.4 All pregnant women were
offered HIV counselling and testing at their ﬁrst visit.
Women who disclosed that they were HIV-infected (ie,
known HIV status before pregnancy) were asked about
prior PMTCT or ART and if they had started lifelong ART.
Pregnancies of HIV-infected women were categorised
according to ART initiation timing: (1) Already on life-
long ART prior to ﬁrst antenatal visit; (2) Started life-
long ART within 6 months of the ﬁrst antenatal visit; and
(3) Not on lifelong ART during pregnancy (as assessed
at delivery). For those patients already on lifelong ART
prior to the ﬁrst antenatal visit, we report the ART
regimen prescribed within 6 months of the ﬁrst visit.
Clinical care and follow-up
Until 2013, pregnant women ﬁrst testing HIV negative
had repeat HIV testing recommended at or after
32 weeks gestation; the 2013 HIV guidelines recom-
mend repeat HIV testing for HIV-uninfected pregnant
women three monthly throughout breast feeding.7 The
2010 and 2013 PMTCT guidelines are summarised in
table 1. Since 2015, South Africa has followed the
WHO recommendation to initiate all pregnant
HIV-infected women on lifelong ART, regardless of
Figure 2 Flow diagram of the Hlabisa pregnancy cohort.
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CD4 count (Option B+).8 9 Before 2010, the ﬁrst-line
regimen recommended for patients with a CD4 count ≤
200 cells/mm3 or WHO stage 4 was stavudine (d4T),
lamivudine (3TC) and either efavirenz (EFV) or nevira-
pine (NVP).10 The 2010 ART adult guidelines recom-
mended that patients already on a d4T-based regimen
continue on this treatment if well tolerated, with early
switch to tenofovir (TDF) with any toxicity.11 Tenofovir
was rolled out according to a phased implementation
plan. Pregnant patients were prioritised if they were
newly initiating ART in April 2010. By April 2011, d4T to
TDF switches were prioritised; hence, there was a lag
with d4T regimen changes for patients who were
initiated prior to April 2010 if side effects were not
severe (Naidu KK (HHTCP Lead, 2016)).
The approximate proportion of patients on d4T regi-
mens in the HHTCP were as follows: (1) by December
2012, ∼20–30% of patients; (2) by December 2013, ∼
10–20%; and (3) by December 2014, ∼5% (Naidu KK
(HHTCP Lead, 2016)).
As per 2015 guidelines, pregnant women are asked to
present for follow-up antenatally six weekly until delivery
or more frequently for complicated pregnancies.9
Women presenting in labour should be counselled and
HIV tested during the ﬁrst stage of labour and offered
routine PMTCT interventions. If not possible, counsel-
ling and testing should be offered postpartum. The
mother should be counselled on feeding practices and
the infant should be tested. Further, women should be
started on lifelong ART before discharge and have cre-
atinine and CD4 count checked at the 3 to 6-day post-
partum visit. Follow-up visits are aligned with the infant
immunisation schedule at 6, 10 and 14 weeks.
What has been measured?
Data collection for the Hlabisa pregnancy cohort is
paper-based with DoH staff collecting routine
demographic, clinical and pregnancy data on women
attending antenatal services (table 2). The database was
designed as an early identiﬁcation tool for pregnant
women requiring further care and to inform clinics of
the appropriate actions at each step in the PMTCT
cascade. Data ﬂow was not unidirectional as Africa
Centre provided action lists, data issues and tracking
reports to DoH staff weekly. Additionally, routine
PMTCT statistics were reported to clinics at least quar-
terly when the HHTCP was operational.
Patient monitoring in the HHTCP, including PMTCT
care, was as follows: (1) Africa Centre staff responsible
for PMTCT data telephoned nurses at the antenatal and
HIV clinics to ﬂag abnormal maternal and infant results
(HIV tests, CD4 and viral loads), to determine if the
appropriate treatment had been provided and if patients
were in care; (2) Patients with abnormal blood results
were telephoned and asked to return to the clinic for
care (Africa Centre staff did not provide blood results
telephonically or disclose conﬁdential information); (3)
Patients eligible for, or on lifelong ART, who did not
return for care were referred to the HHTCP tracking
team; and (4) Clinicians in the HHTCP followed up
patients on lifelong ART with virological failure, includ-
ing pregnant women (latest viral load results above 1000
copies/mL after at least 12 months on a standard ﬁrst-
line regimen), offering genotypic resistance testing as
part of the HIV Treatment Failure Clinic model and the
Southern African Treatment and Resistance Network
(SATuRN),12–14 changing treatment according to DoH
guidelines.7–11
Data were electronically captured at the Africa Centre.
Data were collected at the following times during routine
visits: ﬁrst antenatal visit, follow-up 1 week after the ﬁrst
visit, week 32 (repeat HIV testing) and infant delivery.
The following routine data on HIV care were collected:
(1) CD4; (2) HIV staging; (3) clinical tuberculosis
Table 1 South African prevention of mother-to-child transmission guidelines
Regimen 2010 guidelines 2013 guidelines
PMTCT prophylaxis
(CD4 > 350 and WHO
stage 1/2)
Antenatal zidovudine (AZT) from 14 weeks;
Intrapartum single-dose nevirapine (sdNVP),
3-hourly AZT; Postpartum single dose of TDF
+emtricitabine (FTC)
TDF, 3TC/FTC, EFV to be initiated as soon as
pregnancy is diagnosed (if no active psychiatric
illness or history of renal disease) to be
continued through the postnatal period until
1 week after complete cessation of breast
feeding (WHO Option B)8
Infant regimen: NVP at birth and then daily for
6 weeks, continued as long as any breast
feeding; if formula-fed, infant NVP should stop at
6 weeks
Infant regimen: NVP at birth and then daily for
6 weeks; if the mother on AZT regimen, the
infant should receive NVP at birth, then daily
for 6 weeks to be continued until 1 week after
complete cessation of breast feeding
Lifelong ART (CD4
≤350 or WHO stage
3/4)
TDF, 3TC/FTC, EFV TDF, 3TC/FTC, EFV
Infant regimen: NVP at birth and then daily for
6 weeks irrespective of feeding choice
Infant regimen: NVP at birth and then daily for
6 weeks
ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; FTC, emtricitabine; 3TC, lamivudine; NVP, nevirapine; TDF, tenofovir.
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screening; and (4) ART prophylaxis or treatment
initiation.
Postpartum, data were collected at the 6-week infant
visit. Treatment data for HIV-infected pregnant women
were linked to the HHTCP cohort, described previously,4
to determine details of ART initiation timing, medica-
tion history, including ART adherence, baseline and
follow-up CD4 and viral loads. All test results were col-
lated into a laboratory database and then imported into
the HHTCP database, allowing monitoring of the clin-
ical disease progression of all patients who were initiated
on ART.4
All data, including monitoring laboratory tests for
HIV-infected patients, were as per DoH antenatal and
HIV guidelines. We report on the CD4 count according
to the 2010 and 2013 HIV guideline eligibility for life-
long ART initiation at 350 cells/mm3. 7 11
Data linkage
Pregnancy data were linked to HHTCP data using
names, surnames and identity numbers, or dates of birth
when missing identity numbers. Additional information
such as cellphone numbers and laboratory test dates
were used to verify patient linkage. Trained data cap-
turers linked pregnancy and HIV data sets at capture
into the pregnancy database, and through provision of
monthly lists generated by a data manager. Password
protected data were known only to study investigators
and the data team.
ACDIS linkage
Individuals in ACDIS are assigned an alphanumeric
‘External Identiﬁcation Number (DSID)’, which is
linked to individual identiﬁers, including names and/or
identity numbers. The ‘External ID’ is linked to an
‘Internal ID’ through a highly protected table, accessible
only to the senior data manager. At data capture, an
individual’s ‘Internal ID’ replaces his ‘External ID’,
anonymising all data. The ‘Internal ID’ is added to the
HHTCP and pregnancy databases for all ACDIS patients.
This ‘Internal ID’ provides the link between the ACDIS,
HHTCP and pregnancy databases, allowing de-identiﬁed
data to be extracted from across databases. An ‘Internal
ID’ cannot be used to identify individuals on ACDIS
ﬁeld questionnaires or lists.
FINDINGS TO DATE
The Hlabisa pregnancy cohort consists of women attend-
ing ANC for the ﬁrst time since January 2010. At the
time of data censoring (31 December 2014), the data-
base included 26 520 pregnancies, of whom 25 608
women (96.5%) had HIV test results; 10 469 (40.8%)
were HIV-infected and 15 139 were HIV-uninfected
(ﬁgure 2).
There were 912 (3.4%) women with unknown HIV
status excluded from this analysis (indeterminate,
missing or refused HIV test). Compared to included
women, those excluded were more likely to attend PHC
clinics late in pregnancy at or after 30 weeks (p<0.0001).
Further, included women were slightly younger at ﬁrst
visit (24 years; IQR=20–29 years) relative to excluded
women (26 years; IQR=22–31 years) (data not shown).
HIV-uninfected women were younger (median age
22 years; IQR=19–26 years) than those HIV-infected
(median age 27 years; IQR=23–31 years) and presented
marginally later to PHC clinics for their ﬁrst visit
(median 28 weeks; IQR=20–38 weeks) versus 26 weeks in
HIV-infected women (IQR=18–38 weeks). HIV-uninfected
and HIV-infected women had 7833 (51.7%) and 7287
(69.6%) live-born infants delivered at facilities in Hlabisa
to date, respectively.
Clinical characteristics of HIV-infected pregnant women
Of the 10 469 HIV-infected pregnant women, the data
of 7634 (72.9%) were linked with the HHTCP database,4
to provide detailed information on pregnant women
accessing HIV care. Of the 7634 included women, to
date 972 (12.7%) had subsequent pregnancies recorded.
The linkage with the remaining 27.1% of women was
not possible as incomplete national identifying number
data made probabilistic linkage between two databases
unreliable.
Table 2 Data collected for all pregnant women in the Hlabisa subdistrict (2010–2014)
Data fields Variable list
Demographics Name, national identity number, contact details, date of birth
Clinical visit data Visit date, antenatal clinic name, other antenatal clinic in close proximity, TB screening, parity,
gestational age at first antenatal visit
HIV and related
measures
Maternal HIV status at visit; if HIV-infected, prior PMTCT exposure, ART initiation and monitoring
bloods including CD4 cell count and HIV viral load, full blood count, liver function tests, renal
function tests
Medication history If HIV-infected, date of start of ART, type of treatment, adherence
Delivery data Mode of delivery, infant prophylaxis after delivery; if HIV-infected, maternal antiretroviral treatment or
prophylaxis taken at delivery
Infant data Birth weight, birth head circumference, birth length, feeding choice at birth, DNA PCR result at
6 weeks of age
ART, antiretroviral therapy; PMTCT, prevention of mother-to-child transmission; TB, tuberculosis.
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Overall, 25.1% of women (n=1917) were already on
lifelong ART at their ﬁrst ANC visit; 1349 women
(17.7%) started lifelong ART within 6 months of the ﬁrst
visit of the current pregnancy.
Before 2013, most women who started on lifelong
ART at their ﬁrst antenatal visit received TDF-based regi-
mens; women on lifelong ART before pregnancy were
initiated either on a TDF-based or d4T-based regimen
(table 3). There were a further 2347 women (76.4%)
who received AZT prophylaxis for PMTCT (table 4).
There were 9.6% of HIV-infected women (n=296) who
did not receive any ART during pregnancy; of these, 82
women (27.7%) had CD4 ≤ 350 cells/mm3 and were eli-
gible for treatment. There may have been several
reasons why these women were not started on ART:
movement between clinics and not accessing results;
transfer out of the subdistrict; or death (0.4%) due to
disease progression.
Post-2013, most women established on ART before
their ﬁrst antenatal visit were on TDF-based regimens.
Further, the proportion of women who were initiated on
d4T regimens (13.7%) before their ﬁrst visit were less
than in prior years (25.9%), reﬂecting the phased imple-
mentation plan for ART, with pregnant women priori-
tised to start triple ART.15 Moreover, relative to earlier
years, there was an increase in the proportion of women
on established ART before their ﬁrst visit, and initiated
on ART within 6 months of the ﬁrst visit. All women who
were newly initiated on ART within 6 months of their
ﬁrst antenatal visit were on TDF-based regimens. Of the
1298 women who were not on lifelong ART, most were
started on the ﬁxed dose combination of TDF+FTC
+EFV; and 14% received AZT prophylaxis (table 4). The
proportion of pregnant women who did not receive
ART prophylaxis or were missing data on treatment
decreased post-2013 versus earlier years.
The median maternal age of women not on ARTor ini-
tiating ART within 6 months of the ﬁrst visit was younger
than that of women already on lifelong ARTat pregnancy
diagnosis (table 3). Overall, the median gestational age
at ﬁrst visit was 23 weeks (IQR=17–37 weeks). Across the
years and irrespective of ART initiation, a low proportion
of women had a ﬁrst antenatal visit before 12 weeks.
Despite HIV guideline revisions emphasising the import-
ance of early attendance, over 15% of women attended
their ﬁrst antenatal visit in the third trimester at 25 to
36 weeks gestation. Unexpectedly, there were over 20% of
women who were already on lifelong ART with a ﬁrst
antenatal visit after 37 weeks gestation, both pre-2013
and post-2013; this may suggest women on lifelong ART
had their pregnancy managed while attending the clinic
for HIV treatment. However, this was not standard and
women on established lifelong ART were usually referred
to the ANC for pregnancy care. While the proportion of
women who were newly initiated on ARTwithin 6 months
of pregnancy after 37 weeks fell post-2013, more women
not on lifelong ART attended their ﬁrst antenatal visit
after 37 weeks relative to earlier years. This may be
aligned with guideline revisions to start pregnant
HIV-infected women on ART as soon as possible, or
reﬂect an improvement in data collection with less
missing data on gestational age post-2013.
In general, women who started lifelong ART within
6 months of pregnancy were in better health at ART initi-
ation with a higher median baseline CD4 count, particu-
larly after guidelines revisions in 2013 (table 3). Viral load
monitoring was inadequate during pregnancy, with only
24.2% (n=739) of the women on lifelong ART overall
having a viral load test recorded 6 months before or after
the ﬁrst antenatal visit. Of those with viral loads, 12.0%
(n=89) had virological failure (ie, viral load ≥1000
copies/mL) within 6 months of their ﬁrst antenatal visit.
Overall, preliminary analysis suggests that follow-up in
the HIV programme was over 80% in women on lifelong
ART (n=2768; 80%), at 6 weeks postpartum. Though the
proportion of women not on lifelong ART who did not
return for care declined in later years versus earlier
years, and is likely to be an indicator of better adherence
to triple ART prophylaxis post-2013, there were still over
15% of women not in care post-2013.
DISCUSSION
Data from the Hlabisa pregnancy cohort indicate the
low proportion of women who attended their ﬁrst ANC
visit early in the ﬁrst trimester. Early attendance is
particularly important given the current PMTCT guide-
lines to provide triple ART to HIV-infected women from
the ﬁrst antenatal visit for maternal and infant health.
The younger age of HIV-uninfected pregnant women
compared with those HIV-infected in this cohort is
similar to that of a Sowetan study.16 A possible explan-
ation may be that pregnancy rates decline with HIV
disease progression.17 However, given the expanded
ART use in pregnant women which has been associated
with higher pregnancy rates,18 another likely scenario is
that HIV-infected women may be accessing contracep-
tion and delaying pregnancy as they progress through
the HIV treatment cascade as reported in another Africa
Centre study using surveillance data.19
The improvement in PMTCT coverage and patient
retention post-2013 supports the feasibility and acceptabil-
ity of the 2013 PMTCT revisions. While Malawi reported
an ART coverage increase of ∼49%,20 the ART coverage
progression in our study was more conservative. These
ﬁndings should be contextualised by successes within the
HHTCP with high ART coverage; by July 2011, ∼37% of
all HIV-infected patients were on lifelong ART;6 by 2012,
over 50 000 patients were enrolled with 25 000 individuals
initiated on lifelong ART.6 12 Our study indicates that
over 65% of women were established on ART before
pregnancy and newly initiated on ART within 6 months of
the pregnancy pre-2013. These ﬁndings reinforce South
Africa’s commitment to reduce vertical HIV transmission
and improve maternal health and child survival consistent
with international priorities.21 22
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Table 3 Characteristics of 7634 HIV-infected pregnant women in the Hlabisa subdistrict from 1 January 2010 to 31 December 2014 by ART status
Up to 2012 2013 and later
On lifelong ART before
the first antenatal visit
(N=1295)
Started lifelong ART
within 6 months of the
first antenatal visit
(N=912)
Not on lifelong
ART (N=3070)
On lifelong ART
before the first
antenatal visit (N=622)
Started lifelong ART
within 6 months first
antenatal visit (N=437)
Not on lifelong
ART (N=1298)
Median age, years 30 (26–34) 27 (23–31) 25 (21–29) 31 (27–35) 25 (22–30) 26 (22–31)
GA at first visit, weeks
<12 68 (5.3) 55 (6.0) 177 (5.8) 54 (8.7) 43 (9.8) 59 (4.6)
12–24 363 (28.0) 473 (51.9) 1108 (36.1) 214 (34.4) 240 (54.9) 415 (32.0)
25–37 209 (16.1) 165 (18.1) 631 (20.6) 98 (15.8) 78 (17.9) 200 (15.4)
>37 319 (24.6) 57 (6.3) 436 (14.2) 174 (28.0) 10 (2.3) 416 (32.1)
Missing 336 (26.0) 162 (17.8) 718 (23.4) 82 (13.2) 66 (15.1) 208 (16.0)
Median baseline CD4
count (IQR), cells/mm
166 (105–233) 235 (162–300) 431 (321–568) 187 (125–274) 440 (299–629) 492 (357–656)
Missing 60 37 1290 53 80 340
Baseline CD4 count
≤350 cells 1179 (91.0) 827 (90.7) 532 (17.3) 513 (82.5) 132 (30.2) 184 (14.2)
>350 cells 56 (4.3) 48 (5.3) 1244 (40.5) 56 (9.0) 225 (51.5) 774 (59.6)
Missing 60 (4.6) 37 (4.1) 1290 (42.0) 53 (8.5) 80 (18.3) 340 (26.2)
On TB treatment at initiation
Latest drug regimen
TDF-based 872 (67.3) 768 (84.2) – 480 (77.2) 437 (100) –
Stavudine-based 335 (25.9) 16 (1.8) – 85 (13.7) – –
AZT-based 50 (3.9) 79 (8.7) – 23 (3.7) – –
Unknown 38 (2.9) 49 (5.4) – 34 (5.5) – –
Status
Active 1076 (83.1) 724 (79.4) 1670 (58.5) 560 (90.0) 408 (93.4) 958 (73.8)
Deceased 12 (0.9) 12 (1.3) 10 (0.4) 1 (0.2) – 4 (0.3)
Loss to follow-up 169 (13.1) 155 (17.0) 1172 (41.0) 54 (8.7) 29 (6.6) 240 (18.5)
Transfer out 38 (2.9) 21 (2.3) 4 (0.1) 7 (1.1) – –
Missing 214 96 (7.4)
ART, antiretrovival therapy; AZT, zidovudine; GA, gestational age; TDF, tenofovir; TB, tuberculosis.
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Prior studies before Option B implementation have
reported ∼25–50% of patients of women on ART at
delivery lost to care within 6 months postpartum.23–25
While the proportion of women on lifelong ART
retained in care in this study was high, the proportion of
women initiated on interrupted triple ART prophylaxis
post-2013 was higher than the attrition rate in the
DREAM cohort of pregnant women in Cameroon
initiated on Option B (92.6% at 6 months);26 our study
reports follow-up status at 6 weeks postpartum and it is
possible that retention may deteriorate over time. In
Malawi, ∼17% of pregnant women initiated on Option B
+ were lost to care by 6 months; most women were lost
to follow-up on the day of HIV testing and ART initi-
ation.27 These results emphasise the importance of treat-
ment literacy, particularly as pregnant women start ART
on higher CD4 counts.
Our ﬁnding that 25% of women had viral load testing
highlights a common problem in resource poor set-
tings,28 and encourages policymakers to seek strategies
to overcome this challenge. While pregnancy viral load
monitoring may have improved since the latest HIV
guideline release,9 monitoring of virological failure is
necessary to minimise PMTCT leakages that may
prevent elimination of paediatric HIV. In a population-
based survey including South African data, viral loads
above 1000 copies/mL remained undiagnosed in preg-
nant and breast feeding women.29 Virological failure in
pregnant women on ART underscores the importance of
understanding the different pathways of pregnancy
effect, including physiological, hormonal, drug pharma-
cokinetics and behavioural factors,30 as the risk of drug
resistance increases as more women on ART become
pregnant. Moreover, it is important to engage mothers
as partners in their health since it is clear that antiretro-
viral access does not translate to adherence where
mothers are not empowered and engaged.31–34 Caution
needs to be exercised that budgets that spend enormous
amounts on drugs do not get swamped, resulting in
diminished resources for the equally important psycho-
social elements of management of HIV disease.
Since South Africa has already expanded access to
ART and implemented Option B+, it is likely that more
women will conceive while on established ART. Strong
routine information systems are required to ensure
linkage to care, treatment and disease progression moni-
toring. In future studies, we will link data presented in
this study to the Africa Centre surveillance system, pro-
viding us with an appropriate denominator for the
pregnant population and minimising the challenges
posed by double counting in routine systems, necessary
for using routine data from PMTCT programmes for
‘HIV surveillance’ as recommended by the WHO.35
Additionally, since the pregnancy database was used for
the active PMTCT care monitoring, we were able to
inform DoH staff of the quality and effectiveness of their
services and capacitate staff to improve their routine
data. At a policy level, evidence-based decisions, includ-
ing data from this study, can improve resource allocation
and healthcare performance, particularly as South
Africa expands access to Option B+. The centralised
HIV and pregnancy database in this rural health setting,
including routine data, has allowed us to assess maternal
HIV status and ART guidelines over time, and is comple-
mentary to routine health information systems in South
Africa, including the District Health Information System
and the Three Interlinked Electronic Register (Tier.Net)
to monitor ART provision. As Tier.Net evolves into an
active monitoring system for HIV care, the lessons we
have learnt can advance understanding of data issues,
patient challenges and possible solutions. Moreover,
since the HHTCP includes directly imported laboratory
data,4 the potential for information bias is lessened as
we verify routine data of pregnant women in HIV care.
This cohort is generally representative of the Hlabisa
subdistrict with data on pregnant women attending all
clinics in the area up to 2012, and thereafter still
included two of the busiest antenatal clinics in the sub-
district. Moreover, the HIV prevalence reported in this
study is comparable to the 2012 antenatal HIV preva-
lence in the uMkhanyakhude district (35.2%; 95% CI
29.4−41.5).36 We are currently conducting analyses in
terms of birth outcomes. We also plan a series of ana-
lyses to: (1) determine HIV acquisition risk during preg-
nancy and postpartum; (2) determine the impact of
HIV and ART on birth outcomes; (3) examine the effect
of pregnancy on virological response to ART; and (4)
characterise the effect of sequential pregnancies on
access to clinical care and response to prolonged ART
and birth outcomes.
Strengths and limitations
The main strengths of this cohort include its size and
the ability to model the impact of the HIV programme
on the population due to detailed, longitudinal informa-
tion available about the community and the linkage
between clinical and population data. Accurate charac-
terisation of the cohort will provide an understanding of
the determinants of pregnancy outcomes, and implica-
tions for service delivery in a typical HIV hyperendemic
Table 4 PMTCT regimens of pregnant women in the
Hlabisa subdistrict who were not on lifelong ART from 1
January 2010 to 31 December 2014
ART
prophylaxis
Up to 2012
(N=3070)
2013 and later
(N=1298)
*AZT 2347 (76.4) 186 (14.3)
TDF+FTC+EFV – 967 (74.5)
None 296 (9.6) 95 (7.3)
Missing 427 (13.9) 50 (3.9)
*Inclusive of either sd-NVP, sd-FTC or both.
ART, antiretroviral therapy; AZT, zidovudine; EFV, efavirenz; FTC,
emtricitabine; NVP, nevirapine; PMTCT, prevention of
mother-to-child transmission; TDF, tenofovir.
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rural setting, which is likely to be generalisable to other
resource-limited settings in South Africa.
One of the main challenges common to cohorts of
HIV-infected pregnant women is the attrition rate.24 37 38
High migration rates in the Hlabisa subdistrict may limit
postpartum assessment of long-term maternal outcomes
in this cohort.39 During the HHTCP, Africa Centre and
DoH staff collaborated to follow-up patients lost to care.
It is crucial to follow-up HIV-infected mothers in order
to ensure effective ART delivery for maternal and infant
health; assess maternal adherence and disease progres-
sion; and support safe infant feeding. Using linked
population data sets, the pregnancy outcomes of women
not retained in care may be determined, and through
sensitivity analysis, factors related to poor attrition will be
characterised. The clinical pregnancy data will also be
used to validate the general health surveys on pregnancy
and contraception in the surveillance area, providing sen-
sitivity and speciﬁcity estimates of reporting of pregnancy
within the Africa Centre surveillance area. Since routine
data were collected, it is possible that pregnancy-related
details may be incomplete, resulting in information bias.
Data discrepancies were queried with clinic and hospital
staff prior to data entry. Pregnancy data collected by
nurses and counsellors were also veriﬁed against ante-
natal and delivery registers at clinics and the hospital.
Collaboration
Requests for access to this pregnancy cohort should be
directed to the Africa Centre’s Helpdesk (help@africa-
centre.ac.za) with a ‘Research Dataset Request’ in the
subject line of the email. A data access agreement will
be requested from the researcher and is submitted to
the applicable data custodian. The data user will be noti-
ﬁed once access approval is granted.
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